title: Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.
abstract: We examined the hypothesis that recovery from uncomplicated malaria in patients carrying drug-resistant Plasmodium falciparum is a measure of acquired functional immunity and may therefore be associated with humoral responses to candidate vaccine antigens. Gambian children with malaria were treated with chloroquine in 28-day trials, and recovery was defined primarily as the absence of severe clinical malaria at any time and absence of parasitemia with fever after 3 days. Plasma samples from these children were assayed by enzyme-linked immunosorbent assay for immunoglobulin G (IgG) to recombinant merozoite antigens: apical membrane antigen 1 (AMA-1) and the 19-kDa C-terminal region of merozoite surface protein 1 (MSP-1(19)), including antigenic variants of MSP-1(19) with double and triple substitutions. Antigen-specific IgG was more frequent in children who recovered, particularly that for MSP-1(19) (age-adjusted odds ratios: 0.32 [95% confidence interval, 0.05, 1.87; P = 0.168] for AMA-1, 0.19 [0.03, 1.11; P = 0.019] for recombinant MSP-1(19), 0.24 [0.04, 1.31; P = 0.032] for the recombinant MSP-1(19) double variant, and 0.18 [0.03, 0.97; P = 0.013] for the triple variant). IgG titers to MSP-1(19) and to the triple variant were higher in plasma samples taken 7 days after chloroquine treatment from children who carried resistant parasites but recovered and remained parasite free. Moreover, in children who were parasitemic on day 14 or day 28, there was an age-independent relationship between parasite density and IgG to both MSP-1(19) and the triple variant (coefficients of -0.550 and -0.590 and P values of 0.002 and 0.001, respectively). The results validate the use of this approach to identify antigens that are associated with protection from malaria.
authors.affiliation: MRC Laboratories, P.O. Box 273, Banjul, The Gambia. mpinder@qanet.gm
authors.forename: Margaret
authors.initials: M
authors.lastname: Pinder
authors.forename: Colin J
authors.initials: CJ
authors.lastname: Sutherland
authors.forename: Fatoumatta
authors.initials: F
authors.lastname: Sisay-Joof
authors.forename: Jamila
authors.initials: J
authors.lastname: Ismaili
authors.forename: Matthew B B
authors.initials: MB
authors.lastname: McCall
authors.forename: Rosalyn
authors.initials: R
authors.lastname: Ord
authors.forename: Rachel
authors.initials: R
authors.lastname: Hallett
authors.forename: Anthony A
authors.initials: AA
authors.lastname: Holder
authors.forename: Paul
authors.initials: P
authors.lastname: Milligan
mesh_terms: D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood*; D000953:Antigens, Protozoan / Q000276:immunology*; D000962:Antimalarials / Q000494:pharmacology*; D002648:Child; D002675:Child, Preschool; D002738:Chloroquine / Q000494:pharmacology*; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D007223:Infant; D017780:Malaria Vaccines / Q000276:immunology; D016778:Malaria, Falciparum / Q000188:drug therapy / Q000276:immunology* / Q000469:parasitology; D008565:Membrane Proteins / Q000276:immunology*; D020066:Merozoite Surface Protein 1 / Q000276:immunology*; D018512:Parasitemia / Q000276:immunology; D010963:Plasmodium falciparum / Q000187:drug effects / Q000276:immunology*; D015800:Protozoan Proteins / Q000276:immunology*; D012189:Retrospective Studies
chemical_list: D000913:Antibodies, Protozoan; D000953:Antigens, Protozoan; D000962:Antimalarials; D007074:Immunoglobulin G; D017780:Malaria Vaccines; D008565:Membrane Proteins; D020066:Merozoite Surface Protein 1; D015800:Protozoan Proteins; C090077:apical membrane antigen I, Plasmodium; D002738:Chloroquine